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wherein R1 is phenyl, 4-pyridy1, 3-pyridyl, o_r Z-pyridyl,
and R2 is hydrogen, m- or p-methyl, p-methoxy, m- or
p-chloro, m- or p-bromo, m- or p-?uoro, m- or p-tri

?uoromethyl, 3,4-dich1oro or 3,5-dichloro. The compo
sitions are administered to mammals in an amount to

provide a dosage amount ranging from about 25 rug/kg
to 300 mg/kg.

35 Claims, N0 Drawings
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1,2,3-TRIAZOLE ANTICONVULSANT DRUGS
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particularly relates to certain additional new 1H-l,2,3

triazoles, their methods of preparation, and composi
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This invention relates to lH-l,2,3-triazoles and their
use as a novel class of anticonvulsant drugs, and more

tions for their use in the treatment of convulsive disor

N
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(II)
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BACKGROUND ART

N

CH3

Studies over the past 15 years suggest that the pre

N

vailing rate of epilepsy in the United States is between 5

/

cm-cpn-on

and 20 per 1000, and recent estimates drawn from popu
R
lation surveys indicate that the higher rates are closer to
(In)
the true prevalence. This means that 1 to 4 million 20
Americans suffer from some form of epilepsy. For cer
and Rumanowski, E. 1., US. Pat. No. 3,592,822, 1971)
tain types of seizures there are no speci?c drugs avail
and structure III by Wolf (Wolf, M., US. Pat. No.

able; for seizures that are controlled with currently
available therapy, a new drug may allow a reduction in

the toxic side effects. Despite these facts, between 1960

3,394,143, 1968). In addition certain substituted 1H
25

and 1974, no new anticonvulsant drug was marketed in

l,2,3-triazoles IV and V have been shown to afford
some degree of protection against oxotremorin induced
tremors in mice at 100 mg/kg. (Miller, A. D.,

the United States (with the exception of diazepam,
which was marketed primarily as a minor tranquilizer)

[- NN-R
R2
|

(Vida, J. A. “Anticonvulsants,” Academic Press, New

N/
/

York, 1977). However, since the approval of carbamaz
epine in 1974 and clonazepam in 1975, and sodium di

(IV)

R1
(V)

propylacetate, eterobarb, mexiletine and others in
1977-1978, there has been a resurgence of interest in the 35 I CI, United States, Ger. Pat. No. 2,648,826 (Cl.

CO7D249/O4), 05 May, 1977; US. application No.
626,140, 26th Oct., 1975, 53 pages) and (ICI Americas,
Inc., Belg. 853,978 (Cl. CO7D), 26th Oct. 1977, Appl.
26th Apr. 1977, 11 pages). Compounds of the type IV

development of better anticonvulsant drugs for the
management of epilepsy. Also responsible for this re
newed interest is the establishment of the Anticonvul

sant Screening Project of the Antiepileptic Drug De
velopment (ADD) Program of NINCDS (National

and V have been investigated as potential tranquilizers
or antianxiety agents but not as anticonvulsants.
The 1,2,3-triazoles are a novel group of anticonvul~

Institute of Neurological and Communicative Disorders

sant compounds because their heterocyclic ring system

and Stroke) of NIH, in January, 1975.

is different from that of conventional anticonvulsant

In recent years hundreds of different heterocyclic

drugs. The presently marketed antiepileptic drugs, for

compounds have been synthesized and screened for
anticonvulsant activity. These include mostly ?ve and

the major part, have a dicarboximide function and/or a

disubstituted quaternary carbon group (barbiturates,

hydantoins, succinimides, oxazolidinediones) or closely

six membered ring systems containing up to three or
four heteroatorns and seven membered ring systems

related structure (pyrimidone). On the other hand, the
dicarboximide function, which contributes to the inher
ent hypnotic and sedative activity of the barbiturates
and related compounds, is absent in the triazoles.

related to the diazepines. Among the nitrogen contain
ing heterocycles, a considerable amount of work has
been done in the areas of ?ve membered rings bearing

The chemistry of 1,2,3-triazoles has been extensively
studied (Gilchrist, T. L., and Gymer, G. E., “Advances

one or two nitrogen atoms.

Five membered rings with 3 or 4 nitrogen atoms that

in Heterocyclic Chemistry” Vol. 16, 1974, pp. 33485;

have been investigated, include mostly, 1,2,4-triazo1es

Benson, F. R., and Savell, W. L., Chemical Reviews,
46, 1, 1950; Boyer, J. H., in “Heterocyclic Com
pounds”, Edited by R. C. Elderfield, Vol. 1, p. 384-461,
Wiley, New York, 1961), which also include the appli

and some tetrazoles. Very little has been done on 1H

1,2,3-triazoles (Popp, F. D., In “Anticonvulsants,” J. A.
Vida, Ed. Academic Press, New York, 1977).

cant’s own publications on the synthesis of l-aryl-S

The literature indicates that to date there are only
two references relating to studies on the anticonvulsant

heteroaryl-substituted lH-l,2,3-triazoles. However,

potential of lH-1,2,3-triazoles. Unlike the simple 1-5~
substituted-1,2,3-triazoles of this invention, both these

earlier, no studies have been conducted on 1,2,3

references are to fused ring benzotriazoles of the struc
tures I and II shown below by Gilbert and Rumanowski

(Gilbert, E. E.,

with the exception of the few 1,2,3-triazoles mentioned
triazoles for use as anticonvulsants.
65

As indicated, the present applicant has published two
papers involving her work on triazoles. The publica
tions discuss primarily a convenient general synthetic
route for the preparation of 1,5-substituted 1,2,3

3
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triazoles by permanganate oxidation of the respective
triazolines. (Kadaba, P. K. “Synthesis, International
Journal of Methods in Synthetic Organic Chemistry,”

4

convulsant activity as antiepileptic drugs in the treat
ment of convulsive disorders such as petit mal (absence
seizures) and grand mal (major motor seizures).

No. 9: September, 1978, pp. 694-695). (Kadaba, P. K.,

In one aspect of the invention, it relates to novel

“Journal fur praktische Chemie,” Vol. 324, 1982, pp.

anticonvulsant compositions which comprise as the
active ingredient a compound selected from those of the

857-864.)
In both these publications, however, there is no dis

following formulae:

closure of the use of any of the 1,2,3-triazole com
pounds as anticonvulsants.

SUMMARY OF THE INVENTION

10

It is accordingly one object of the present invention
to provide certain triazoles as anticonvulsant drugs.
A further object of the present invention is to provide
several new lH-l,2,3-triazoles and methods for their use

wherein R1 is phenyl, 4-pyridyl, 3-pyridyl, or 2-pyridyl,

in the treatment of convulsive disorders.
A still further object of the present invention is to

and R2 is hydrogen, m- or p-methyl, p-methoxy, m- or
p-fluoro, m- or p-chloro, m- or p-bromo, m- or p-tri

provide anticonvulsant compositions containing as the

essential ingredient certain lH-l,2,3-triazoles and use of
fluoro methyl, 3,4-dichloro or 3,5, dichloro substituents.
these triazoles as antiepileptic drugs in the treatment of 20
In a further aspect of the present invention, new com
convulsive disorders such as epilepsy.
pounds are provided which have anticonvulsant activ
Other objects and advantages of the present invention
ity and which are of the following general formulae:
will become apparent as the description thereof pro
ceeds.
In satisfaction of the foregoing objects and advan

tages, there is provided by this invention anticonvulsant

R]

compositions comprising as the active ingredient, a
compound selected from those of the following formu

N

H

lae:

|

N

30

éN

In the above formulae, R1 is 3-pyridyl, or 4-pyridyl,
and R2 is m-methyl, m- or p-fluoro, m- or p-bromo, m
or p-chloro, m- or p-tri?uoromethyl, 3,4-dichloro, or

3,5-dichloro substituent.
N

35

wherein R1 is phenyl, 4-pyridyl, 3-pyridyl, or Z-pyridyl,
and R2 is hydrogen, m- or p-methyl, p-methoxy, m- or
p-fluoro, m- or p-chloro, m- or p-bromo, m- or p-tri

There is further provided by this invention methods
for administration of the anticonvulsant composition to
mammals including animals and humans.
The triazoles of this invention may be prepared by

the oxidation of 4,5-dihydro-lI-I-1,2,3-triazoles (A2

fluoromethyl, 3,4-dichloro, or 3,5-dichloro substituent.

l,2,3-triazolines), which in turn, are prepared by the

Also provided are methods for administration of the
anticonvulsant compositions of this invention to mam
mals in the treatment of convulsive disorders such as

reaction of diazomethane with Schiff bases as described,

for example, by Mustafa, A., (J. Chem. Soc.), 234
(1949), and by Buckley, G. D., (J. Chem. Soc), 1850,

epilepsy including petit mal and grand mal.

(1954). Further methods of preparation of 1,2,3-triazo

There is also provided by this invention certain new 45 lines involving 1,3-dipolar cycloaddition reactions are
compounds which are useful as anticonvulsant drugs.
described in the applicant’s own publications in Kadaba,
These compounds may be characterized by the follow
et al. (J. Org. Chem. 26, 2331 (1961), by Kadaba in

ing general formulae:

“Tetrahedron,” 22, 2453 (1966), by Kadaba in “Tetrahe
dron,” 25, 3053 (1969) and J. Heterocyclic Chem, 12,
143, (1975). This reaction proceeds generally in accor
dance with the following equation. (Eq. 1)
(Eq- 1)
55

wherein R1 is 4-pyridyl, or 3-pyridyl, and R2 is m

Dioxane + H2O

+ CHZNZ Room temperature 5

methyl, m- or p-?uoro, m- or p-chloro, m- or p-bromo,
m- or p-trifluoromethyl, 3,4-dichlor0, or 3,5-dichloro.

DESCRIPTION OF PREFERRED
60
EMBODIMENTS
As indicated above, this invention relates to certain
1,2,3-triazoles which are useful as anticonvulsants. The
triazoles of this invention are to be named as lH-1,2,3
triazoles. The triazoles of this invention are substituted 65

in the l and 5 positions by aryl or heterocyclic groups
which may also contain substituents. The triazole com

pounds of this invention have potent to moderate anti

R2

111T- Nl
N/
/

N

A2-l,2,3-Triazolines
In the above equation R1 and R2 are as de?ned above.
Kinetic studies on solvent effects of this reaction
indicate that protic solvents such as water have a gen

4,610,994

5

eral accelerating effect on the reaction and by carrying

6

cit and thus have an estimated protective index of
greater than 1.

out the addition reaction in an aqueous dioxane solution,

high yields of triazolines are produced.
The 1,2,3-triazolines undergo smooth oxidation to
1,2,3-triazoles, using potassium permanganate in a two
phase system (benzene-water or chloroform-water), in

The following table presents the results of these tests
with respect to certain compounds of the present inven
tion. This Table l identi?es the speci?c compounds
tested by chemical name, and provides the anticonvul
sant activity based on classi?cation in Group I or Group

the presence of a phase-transfer catalyst such as tet

rabutylammonium chloride (Kadaba, P. K., Synthesis,

11.

694, 1978 and Kadaba, P. K., J. prakt. Chem., 324, 857,
1982) in accordance with the following equation.

TABLE I

(Equation 2)
Compound
l. l-(p-Chlorophenyl)-

I

5-phenyl-lH—l,2,3-triazole

NBu4Cl (Catalyst)

Benzene-water

Anticonvulsant Activity
Group Classi?cation

E

15

2. l-(p-Bromophenyl)-

I

20

The permanganate oxidation of triazolines to tria 25
zoles provides a general method for the synthesis of
both 1,5-diaryl and l-aryl-5-heteroaryl substituted 1H
l,2,3-triazoles. The reaction is superior to triazole syn
thesis by azide addition to acetylenes. The lack of reac
tivity of acetylenes as well as the formation of isomeric

1,4- and 1,5-substituted triazoles in the cycloaddition of
phenyl azide to aryl acetylenes limit the utility of the
acetylene-azide addition reaction in triazole synthesis.
(Gilchrist, T. L., and Gymer, G. E., Adv. Heterocycl.
Chem., 16, 33, 1974; Stephan, E., Bull Soc. Chim., Fr.,
7-8, 364, 1978; L’abbe, G. and Hassner, A., Bull. Soc.

35

Chim Belg. 80, 209, 1971; Alonso, G., Garcia-Lopez, M.
T., Garcia-Munoz, G., Madronero, R., and Rico, M., J.

Heteracycl. Chem, 7, 1269, 1970).
As pointed out, the triazole compounds and resulting

40

anticonvulsant compositions of this invention are useful
in the treatment of convulsive disorders. The potency
of the compounds range from those which are very

potent to those of moderate potency. A series of tria

zoles of this invention has been evaluated in Phase I 45
As shown in the above table, the most potent com
anticonvulsant screening using two seizure models in
pounds are compounds 1,2,3,7,9,10,l1,12 and 14. These
the mouse, the maximal electro-shock seizure (MES)
compounds belong to Class I and with the exception of
test and the subcutaneous pentylenetetrazole (Met
compounds 7 and 9, the remaining seven compounds do
razole) seizure threshold (scMet) test. These two meth
not exhibit signi?cant signs of neurological de?cit at
ods of seizure provocation elicit reliably well character
their effective dose levels. In addition, compounds 8
ized seizure phenomena (Chen. G., et al. Proc. Soc.

Exp. Biol. Med., 87, 334 (1954), and together have been

and 13 in Class II are also effective anticonvulsant com

pounds because they give 100% protection at 300
shown suf?cient to identify all compounds known to
mg/kg, without any signs of neurological de?cit. Thus,
demonstrate anticonvulsant activity in other tests.
Based on the Phase I screening results, the compound
these nine compounds, l,2,3,8,l0,1 1,12,13 and 14, repre
tested is placed in one of three categories. Those failing
sent the preferred embodiments of the anticonvulsant
to demonstrate anticonvulsant activity at doses up to
compositions of this invention. Compound 10 which is
300 mg/kg are considered inactive. Class II compounds
1-(para-chlorophenyl)-5-(3-pyridyl)-lH-l,2,3-triazo1e
show anticonvulsant activity at doses greater than 100
and Compound 11 which is 1-(p-bromophenyl)-5-(3
mg/kg or show activity at 100 mg/kg which is not 60 pyridyl)-lH-l,2,3-triazole are the most preferred com
reinforced by similar activity at 300 mg/kg. Thus com
pounds of this invention.
pounds of Class or Group II demonstrate anticonvul
As indicated above, although other preparative reac
sant activity without signs of neurological de?cit, but
tions could be used for the triazoles of this invention,
do not have signi?cant potency. The Class I compounds
the permanganate oxidation of 1,2,3-triazolines in a
are those which are most promising as anticonvulsants. 65 phase-transfer catalyzed reaction is the method of
They demonstrate anticonvulsant activity in either the
choice for the synthesis of 1,5-substituted triazoles,
MES test or the scMet test, or both at doses of 100

mg/kg or 30 mg/kg without signs of neurological de?

especially l-aryl-S-heteroaryl-lH-1,2,3-triazoles (Equa

tion 2). Several l-aryl-S-heteroaryl-1,2,3-triazoles were

4,610,994

7

prepared for the ?rst time by this method (P. K.

Kadaba, Synthesis, 694, 1978).

8

thereto. In the examples and throughout the speci?ca
tion, parts are by weight unless otherwise indicated.

A mixture of 1,2,3-triazoline (0.005 mol) in benzene

EXAMPLE 1

(75 ml), potassium permanganate (0.025 mol) in water

Using the reaction of Equation 2 described above

(100 ml) and tetrabutylammonium chloride (0.5 mmol)
was heated under re?ux with magnetic stirring for 4

involving potassium permanganate oxidation of 1,2,3

hours or more. The reaction mixture was then cooled to

triazolines, the following compounds were prepared. In
the following Table 2, melting points and yields are
given for new compounds prepared.

room temperature, treated with sodium sul?te to de

stroy excess potassium permanganate and ?ltered under

suction to remove the manganese dioxide. The residue 0
was washed twice with hot benzene and combined with
Compound
benzene extracts of the ?ltrate, washed with water,

TABLE 2
M. Pt. °C.

Yield %

dried, and evaporated under reduced pressure. An oily
residue was obtained, which upon cooling and tritura
tion with diethylether, yielded the triazole as a crystal
line solid. Recrystallization from diethyl ether or a mix
ture of petroleum ether and acetone or methanol

yielded the analytically pure products. Chloroform can
easily be used in place of benzene in certain reactions.
Furthermore, since Schiff bases (imines) bearing a
range of aromatic or heterocyclic substituents can be

readily prepared, the CHgNg-imine reaction is particu

109-1005

larly suited for the synthesis of the various 1,5-sub
stituted triazolines required for the oxidation reaction.

139-140

The addition of diazomethane to imines occurs regiose
lectively and thus there is no problem of isomeric tri
azole formation as in azide-acetylene addition reactions.
As pointed out above, this addition is preferably carried
out in aqueous dioxane solutions according to the appli

60

130-131

cant’s previous publications. In a typical preparation,
the Schiff base is dissolved in a cold, freshly prepared
solution of CHZNZ in wet dioxane. The reaction mixture
is then allowed to stand at 15°-20° C. for 2—4 days in the
case of the reactive anils and 6-7 days in the case of the
slow reactions. At the end of this period, the mixture is
cooled and diluted with water to precipitate the triazo
line adduct.

120-122

70

136-139

70

155-1565

80

160-162

74

87-89

125-1265

The CHZNZ for the reaction is prepared conveniently

76-79

47

from N,N'-nitrosomethylurea in the same manner that 40
1~ undistilled ethereal solutions are obtained, but using

115-116

47

122-1215

66

1,4-dioxane in place of diethyl ether. Dioxane is the
solvent of choice because of its easy miscibility with
water and the ease with which it can be substituted for

diethyl ether. The CHZNZ solution thus obtained con 45
These compounds were identi?ed through their ele
tains water in suf?cient amounts to catalyze the reaction
mental analyses, characteristic melting point (unlike
and is used immediately.
1,2,3-triazolines, 1,2,3-triazoles do not decompose at
The'Schiff bases are prepared using standard proce
their melting point with vigorous evolution of nitro

dures by heating a mixture of the appropriate adehyde
gen), and NMR spectra, which exhibit a sharp singlet
and amine in ethanol or alternatively by heating the 50 signal in the 88.0 region characteristic of the 4-CH
mixture in benzene followed by azeotropic removal of
proton in the l,5-substituted-1,2,3-triazoles. The CH
the water, the latter being a more suitable procedure in
signal for the 1,4-substituted triazoles would appear at
dif?cult cases.

_

8<8 (Stephan, E., Bull. Soc. Chim. FL, 7-8 364, 1978).

The anticonvulsant compounds of the present inven

These compounds were then evaluated in accordance

tion may be administered to animals or humans at doses 55 with the methods set forth above for anticonvulsant
ranging from about 25 mg/kg up to about 300 mg/kg.
characteristics. The results are set forth in Table 1

Preferred levels of administration range from about 25
mg/kg up to 100 mg/kg. The active ingredients or
compounds of this invention may be administered in
any desired form by injection or in the oral form. Con
ventional adjuvents and carriers may be employed in
combination with about 0.001 to 2.0 wt.% of the active

ingredient. Thus the anticonvulsant compositions of this
invention may be administered in pill form or by injec

above. As pointed out with respect to Table l, the com

pounds demonstrate anticonvulsant activity in either
the MES test or the scMet test or both. Compounds of

Class I demonstrate this activity at doses of 100 mg/kg
or 25 mg/kg without signs of neurological de?cit and
thus have an estimated protective index of greater than
1.

EXAMPLE 2
tion. As indicated above, the dosage rate ranges from 65
about 25 mg/kg up to about 300 mg/kg.
One of the compounds, Compound 10, which is 1
The following examples are presented to illustrate the
(parachlorophenyl)-5-(3-pyridyl)- lH-1,2,3-triazole, was
evaluated in further studies to provide additional infor
invention but it is not to be considered as limited

9
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mation as to its general pro?le of anticonvulsant activ

10

Bic Test), subcutaneous Picrotoxin Seizure Threshold

ity.

Test (sc Pic Test), and the subcutaneous Strychnine
Seizure Pattern Test (sc Strych Test). Except for the sc

Thirty minutes after administration, Compound 10 of
this invention exhibited anti-maximal electroshock

Strych Test, these tests measure the ability of anticon

(MES) at 30 mg/kg and anti-Metrazol (sc Met) activity

vulsants to afford complete protection against threshold
seizures induced by the subcutaneous injection of the
CD97 of the convulsant agent. The so Strych Test mea

at 300 mg/kg. Rotorod toxicity was seen in all four

animals given 300 mg/kg of the test substance. Four

hours after administration, the candidate substance was
sures the ability of the test substance to abolish all tonic
effective by the MES and scMet tests at 300 mg/kg; one
components of seizures induced by the subcutaneous
of two animals was also toxic at this dose level. Thus, c. 0 injection of the CD97 of strychnine. The sc CD97 of

the pro?le of anticonvulsant activity of Compound 10
was characterized by the ability to modify maximal

Metrazol, bicuculline, picrotoxin, and strychnine in
mice is 85, 2.70, 3.15, and 1.20 mg/kg, respectively; the

electroshock seizure pattern and to elevate the Metrazol
seizure threshold in nontoxic doses. Accordingly, the

sc CD97 for Metrazol in rats is 70 mg/kg.
The pro?le of toxicity for each test drug was estab

test substance (Compound 10) was subjected to Phase II

lished by the following procedures: Firstly, the minimal

Anticonvulsant Quanti?cation in Mice i.p., Phase III
Toxicity Pro?le in Mice i.p., Phase IV Anticonvulsant
Quanti?cation in Mice p.o., Phase V Antiepileptic Drug

neurotoxic dose (TD50) was determined by the rotorod
procedure at the time of peak neurotoxic effect. When a
normal mouse is placed on a knurled rod one inch in

Differentiation in Mice i.p., Phase VI Anticonvulsant
diameter rotating at a speed of six rpm it can maintain its
Quanti?cation in Rats p.o., and Phase VII Chronic 20 equilibrium for long periods of time. Neurological de?
Administration in Rats p.o. (tolerance, hexobarbital,
cit is indicated by inability of the mouse to maintain its
and liver microsomal enzyme studies). The results ob
equilibrium for one minute in each of three trials on this
tained provided the basis to compare the anticonvulsant
rotating rod. Neurological de?cit in rats is indicated by
activity and toxicity of Compound 10 with those of
ataxia, loss of placing response and muscle tone. Se

clinically useful antiepileptic drugs.

In these experiments, male albino mice (CF No. 1
strain; 18 to 25 g wt) obtained from Charles Rivers,
Wilmington, Mass, and male albino rats (Sprague Daw
ley, 100 to 150 g wt) obtained from Simonsen, Gilroy,
Ca1., were used as experimental animals. All animals
were allowed free access to both food (S/L Custom

Lab Diet-7) and water, except when they were re

moved from their cages for the experimental procedure.
Compound 10 was compared with four prototype

antiepileptic agents (phenytoin, phenobarbital, ethosux
imide, and valproate). Compound 10 was administered

in the requisite volume of 30% polyethylene glycol 400,

whereas phenytoin, phenobarbitol, ethosuximide, and

25

condly, the overt signs and symptoms of toxicity in
duced by each prototype agent and test substance were

determined by giving two mice either lTD50, 2TD50’s,
or 4TD50’s and observing and testing them 10, 20, and

30 minutes and l, 2, 4, 6, 8, and 24 hours after drug
administration for the onset, intensity, and type of overt

toxicity. These observations also provide preliminary
information essential for the subsequent determination
of the HD50 and LD50. The HDSO represents the me
dian dose at which 50% of animals lose their righting
35 re?ex. The 24-hour LD50 represents the median dose

which causes death in 50% of the animals within 24

hours.

Except for bicuculline, all convulsant drugs (Metra

valproate were administered in 0.9% sodium chloride
zol, picrotoxin, and strychnine) administered to mice
solution. The drugs were administered either orally or 40 were dissolved in suf?cient 0.9% sodium chloride solu
intraperitoneally in a volume of 0.01 ml/g body weight
tion to make a concentration of 0.85%, 0.032%, and
in mice and 0.04 ml/lO g in rats. All tests were con
0.012%, respectively. Bicuculline was dissolved in 1 ml
ducted at the previously determined time of peak drug
of warmed 0.1N HCl with the aid of a micro-mixer and
effect. To determine anticonvulsant potency and toxic
suf?cient 0.9% sodium chloride added to make a
ity, groups of at least eight mice or rats were tested with
0.027% solution; the solution was used 15 to 45 minutes
various doses of the drug until at least four points were
after preparation. Metrazol (3.5%) was administered to
established between the limits of 100% protection or
rats in a solution of 0.9% sodium chloride.
toxicity and 0% protection or toxicity. The dose of drug
All convulsants were administered subcutaneously
required to produce the desired endpoint in 50% of
into a loose fold of skin on the back of the neck in a
animals (EDSO) in each test, the dose eliciting evidence
volume of 0.01 ml/g body weight in mice; Metrazol was
of minimal neurological toxicity in 50% of animals
injected in a volume of 0.02 ml/l0 g body weight in

(TD50), the 95% con?dence interval, the slope of the

rats. The convulsant drugs were administered at the

‘regression line, and the standard error (S.E.) of the
previously determined time of peak anticonvulsant ac
slope were then calculated by means of a computer
tion of the drug under study. Except for picrotoxin
program written by NINCDS.
55 treated animals, the mice (eight animals/group) were
The pro?le of anticonvulsant activity for each sub
then observed for at least 30 minutes for the presence or
stance was established by ?ve tests: one electrical and
absence of a seizure. The animals treated with picro
four chemical. The electrical test employed was the
toxin were observed for periods of 45 to 60 minutes for
maximal electroshock seizure pattern test. This test
the presence or absence of a seizure. Except for strych
measures the ability of the test drug to abolish the hind 60 nine, absence of a ?ve-second episode of clonic spasms
limb tonic-extensor component of maximal electro
(threshold seizure) was taken as protection. In the case

shock seizures (mice, 50 mA; rats, 150 mA; 60 Hz, cor

of strychnine, complete abolition of the hindleg tonic

neal electrodes, 0.2 sec stimulus duration); this amount
extension was taken as protection.
of current is approximately six times the threshold and
The results obtained in Phase II Anticonvulsant
reveals the ability of the test substance to prevent sei 65 Quanti?cation Studies in Mice i.p., are shown in Table
zure spread. The four chemical tests include the subcu
3. It may be seen from the table that the times of peak

taneous Metrazol Seizure Threshold Test (sc Met Test),
subcutaneous Bicuculline Seizure Threshold Test (sc

effect (TPE) of the ?ve compounds range from 15 min
utes to two hours. The TPE of Compound 10 was 60
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minutes for the rotorod toxicity test and 30 minutes for

by the sc Met test with P.I.’s of 3.38, 2.87, and 5.24,

the anticonvulsant tests.

respectively.

With respect to anticonvulsant activity, phenobarbi
tal, Compound 10 of this invention and valproate had

Phase III, Toxicity Pro?le Studies in Mice given
lTDSO, 2TD50’s and 4TD50’s of Compound 10 intra

signi?cant anticonvulsant activity in nontoxic doses as
measured vby both the maximal electroshock seizure
(MES: EDSO’s: 21.78, 65.76, and 271.66 mg/kg. respec
tively) and subcutaneous Metrazol seizure (scMet;

5

peritoneally, were also carried out on the compounds.

The toxicity pro?le induced by 1TD50 of Compound
10 was characterized by decreased motor activity, roto

rod toxicity, ataxia, and decreased respiration. In addi
tion to these symptoms, animals given 2T50’s of Com
EDSO’s: 13.17, 26.95, and 148.59 mg/kg, respectively)
tests. In contrast to the above, phenytoin had signi?cant 1O pound 10 exhibited cyanosis, muscle relaxation, and loss
of righting re?ex. Both mice given 4TD50’s of Com
anti-MES activity (EDSO: 9.50 mg/kg) but did not pro
pound 10 of this invention displayed all the symptoms
tect against subcutaneous Metrazol seizures. Ethosuxi
characteristic of those given 1TD5O and 2TD50’s of the
mide, on the other hand, was not able to protect mice
test drug; however, the symptoms were more intense.
from maximal electroshock seizures but exhibited signif
icant anti-Metrazol activity in nontoxic doses (EDSO: 15 Animals given 1TD50 were normal after 24 hours,
whereas both mice given 2TD50’s were dead after 24
130.35 rug/kg).
hours; one animal given 4TD50’s was dead 4 hours after
With regard to minimal neurotoxicity, ethosuximide
and valproate were the least toxic (TDSO’s: 440.83 and

drug administration and the other was dead at 24 hours.

425.84 mg/kg, respectively), whereas phenytoin and

A more detailed qualitative description of the pro?le of

phenobarbital were the most toxic with TD50’s of 65.46 20 acute toxocity in mice (i.p.) of Compound 10 as well as

and 69.01 mg/kg, respectively. The Compound 10 of

phenytoin, phenobarbital, ethosuximide, and valproate

this invention was intermediate in toxicity with a TD50

is shown in Table 4. In addition, the hypnotic dose 50
(HDSO) and lethal dose 50 (LD50) of these compounds

of 244.51 mg/kg.
TABLE 3

PROFILE OF ANTICONVULSANT ACTIVITY OF
INTRAPERITONEALLY ADMINISTERED COMPOUND 10
AND SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE.
ADD No.

Time Rotorod
of Test TD50

Substance

(hrs)

Compound 10

1, 1, 1 244.51
(22182-27517)

[13.86]
Phenytoin

Phenobarbital

Ethosuximide

2, 2, 2 65.46

4}, 1, 1

ED50 (mg/kg) and PI

(mg/kg)

MES

sc MET

65.76
(51.82-83.19)

26.95
6.89-55.08)

[5.43]

[1.21]

9.50

(52.49-72.11)

(23.13-10.44)

[15.23]

[13.66]

[E]

69.01

21.78

13.17

(14.99-25.52)

(5.87-15.93)

[24.67]

[14.92]

[5.93]

%, Q, § 440.83

No protection

@

up to 1000

[18.37]
1, I, .1, 425.84

@Zl

up to 300

(62.84-72.89)

(38309-48534)

valproate

No Protection

IE]

130.35
(11099-15045)

[10.06]
271.66

148.59

(36891-45040)

(24697-33789)

(12264-17702)

[20.34]

[12.83]

[11.84]

( ) 95% Con?dence interval

[ ] Slope, regression line
" Protective Index (P.l.) = TDSO/EDSO

It may also be seen from Table 3 that the protective 60

indices (TD50/ED50=P.I.) by the MES test range
from <O.44 for ethosuximide to 6.89 for phenytoin. The

are also listed. As shown in the table, the HDSO and
LD50 of Compound 10 were not signi?cantly different

P.I.’s of the remaining three compounds (valproate,

(525.97 and 569.26 mg/kg, respectively). The HDSO for

Compound 10 was signi?cantly higher than that for
Compound 10 of this invention and phenobarbital) are
1.57, 3.72, and 3.17, respectively. The P.I.’s of com 65 either phenobarbital (135.45 mg/kg) or phenytoin
(178.34 mg/kg), but signi?cantly lower than that for
pounds by the sc Met test range from <O.22 for phenyt
either valproate (885.53 mg/kg) or ethosuximide
oin to 9.07 for the compound of this invention. Ethosux

imide, valproate, and phenobarbital were also effective

(850.61 mg/kg).
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TABLE 4
PROFILE OF ACUTE NEUROTOXICXTY
OF INTRAPERITONEALLY ADMINISTERED COMPOUND 10 AND SOME PROTOTYPE
ANTIEPILEPTIC DRUGS IN MICE

ADD No.
or
Name

l X TDSO

Pro?le of‘ Acute Toxicity, Mice i.p.
2 X TD50
4 X TDSO

Compound

(245 mg/kg) At 1 hr one of two
animals exhibited decreased

(490 mg/kg) Both animals had
decreased motor activity,

motor activity, ataxia, rotorod

ataxia, and rotorod toxicity at

activity, ataxia, rotorod tox-

toxicity, and decreased respiration. The remaining animal
showed only ataxia. Both were
normal at 24 hrs.

10 min. In addition, decreased
respiration was evident at 20
min, and muscle relaxation with
cyanosis at 30 min with loss of
righting re?ex at 2 hrs. One

icity, muscle relaxation and
decreased respiration with
cyanosis. One animal had loss
of righting re?ex. The other
animal lost its righting re?ex

animal regained its righting
re?ex at 4 hrs. Both animals

at 1 hr. One animal was dead
at 4 hrs, the remaining animal

10

Phenytoin

(65 mg/kg) Increased motor
activity, slight ataxia, fre~
quent grooming, nervous be-

(980 mg/kg) At 20 min, both
animals had decreased motor

were dead at 24 hrs.

was dead at 24 hrs.

(130 mg/kg) Mild ataxia,
periods of sedation, spasms of
arching, rolling, straub tail,

(260 mg/kg) Toxic manifestations identical to 2XTD50. At
1 hr, righting re?ex absent,

m
LDSO“
(mg/kg)
525.97
(473.77-564.48)
20.18

'

569.26
(52098-64059)
[14.55]

178.34
(15293-1954)
14.03

havior, and straub tail,

ptosis, and respiratory de-

longer periods of sedation,

animals were not toxic by the

pression. Later, spasms re-

and spasms reduced to head

(21644-25910)

duced and sedation increased.

twisting and uncoordianted

[15.89]

At 24 hrs, toxicity present,
other symptoms less pronounced.

movements; respiratory de~
pression continued, mice dead

rotorod test.

229.61

at 24 hours.

Pheno-

(70 mg/kg) Ataxia with in-

(140 mg/kg) Ataxia with in-

(280 mg/kg) Ataxia with in-

barbital

creased motor activity followed

creased motor activity followed

creased motor activity follow-

by sedation and ptosis with

by loss of righting re?ex,

ed by loss of righting re?ex,

one of two animals toxic by
the rotorod test up to 4 hrs.

tremors, re?ex scratching,
ptosis, sedation and some

tremors, re?ex scratching,
ptosis, sedation, anesthesia

respiratory depression. Both
mice regained their righting

with analgesia and respiratory
depression. Both animals

re?ex at 2 hrs and one of two
was still toxic by the rotorod

became cold to touch and
cyanotic with increased res

test at 8 hrs.

piratory depression; death
occurred at approximately 3

135.45
(11490-17742)

8.41
264.70
(241.55-285.52)

[15.95]

and 6 hrs.

Etho-

(440 mg/kg) Uncoordinated

(800 mg/kg) Uncoordinated

(1760 mg/kg) Uncoordinated

suximide

motor activity, re?ex scratch-

motor activity, re?ex scratch~

motor activity, respiratory

ing, respiratory depression,

ing, loss of righting re?ex

depression, hypnosis and

[16.43]

ataxia.

at 4 mins but regained in 20

anesthesia followed at later

1752.23

mins, hypnosis followed at

time intervals by cyanosis

later time intervals by seda-

and death at 24 hrs.

850.61
(751.19—917.93)

(1607.02-1866.64)
[14.75]

tion, ataxia, ptosis, vasodila
tion and diarrhea.

Valproate

(400 mg/kg) Mild ataxia, with
one of two mice toxic by the
rotorod test. Appeared
normal at the end of 4 hrs.

(800 mg/kg) Ataxia, with both
animals toxic by the rotorod
test, normal respiration and
some sedation. Both animals

appeared normal at 4 hrs.)

(1600 mg/kg) Both animals died.
885.53
(At 3XTD50 there was respira

tory depression, ptosis, hypnosis but no analgesia. These
animals were dead at 4 hrs.)

(82086-95704)
12.46]
1104.62

(1021.54-1253.66)
[11.41]

The LD50 (569.26 mg/kg) for Compound 10 was signif
icantly higher than that for either phenytoin (229.61‘
mg/kg) or phenobarbital (264.70 mg/kg); however, it
was signi?cantly lower than that for either valproate

(1104.62 mg/kg) or ethosuximide (1752.23 mg/kg).

phenobarbital was somewhat less potent by the MES

test (ED50: 20.09 mg/kg). The test compound (Com
The anticonvulsant activity and minimal neurotoxic
pound 10) on the other hand, was 1/6 and 1/ 15 as po
dose (TD50) for Compound 10 as determined by Phase
tent as phenobarbital and phenytoin, respectively, by
IV studies, Anticonvulsant Quanti?cation in Mice p.o., 55 the MES test with an ED50 of 131.67 mg/kg. When
indicated that the TPE of Compound 10 after oral ad
evaluated by the subcutaneous Metrazol threshold test
ministration was six hours by the rotorod test and one

hour by the anticonvulsant tests. Except for Valproate,
the four prototype agents exhibited TPE’s that were not

after oral administration, phenobarbital was the most

potent (ED50: 12.59 mg/kg) and Valproate was the least
potent (ED50: 388.31 mg/kg). The other two com

signi?cantly different from those observed after the 60 pounds (Compound 10 and ethosuximide) were essen
intraperitoneal administration of these agents. Valpro
tially equal in potency by the sc Met test with EDSO’s of
ate had a TPE of one to two hours after oral administra
135.67 and 192.21 mg/kg, respectively.
tion vs one-fourth hour after intraperitoneal administra
By the oral route of administration in mice, Com~
tion.
pound 10, ethosuximide, and Valproate were essentially

With respect to anticonvulsant activity as measured 65 equitoxic (TD50’s: 729.08, 879,21, and 1264.39 mg/kg,
by the MES test, phenytoin was again the most potent
respectively). Phenytoin and phenobarbital were the
(ED50: 9.04 mg/kg), whereas valproate was the least
most toxic with quite similar TD50’s (86.71 and 96.78

potent (ED50: 664.80 mg/kg). Compared to phenytoin,

mg/kg. respectively).
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The PI. for Compound 10 is 5.54 by the MES test,

whereas valproate was the least potent (ED50: 489.54

whereas the P.I.’s for phenytoin, phenobabital, ethosux
imide, and valproate are 9.59, 4.82, <0.44, and 1.90,
respectively. The P.I. for Compound 10 by the sc Met
test is 5.37, whereas those for phenytoin, phenobarbital,
ethosuximide, and valproate are <0.29, 7.69, 4.56, and
3.26, respectively. Thus, the RI. for Compound 10 of
this invention by the MES test compares very favorably
with the PI. for phenobarbital (5.54 and 4.82 respec
tively), whereas the PI. for Compound 10 by the sc Met
test (5.37) is lower than that for phenobarbital (7.69),
but higher than that for either ethosuximide (4.56) or

mg/kg). The EDSO’s of phenytoin and Compound 10
by this test were 29.82 and 49.89 mg/kg, respectively.
When compared on the basis of the sc Met test, pheno
barbital was the most potent (ED50: 11.55 mg/kg) and
Compound 10 was the least potent (ED50: 329.18

mg/kg). Ethosuximide and valproate were less potent
than phenobarbital by this test with ED50’s of 53.97 and

179.62 mg/kg, respectively.
With regard to neurotoxicity, Compound 10 and
phenobarbital were essentially equitoxic (44.48 and
61.09 mg/kg, respectively) and ethosuximide and phe
nytoin the least toxic (TD50’s: 1012.31 and >3000
mg/kg, respectively). Valproate was intermediate in

valproate (3.26).
The results obtained in Phase V evaluation, Anti

toxicity with a TD5O of 280.26 mg/kg.
The P.I.’s by the MES test vary from 0.57 for valpro
ate, < 0.84 for ethosuximide, and 0.89 for Compound 10

epileptic Drug Differentiation in Mice, indicated that
the pro?le of anticonvulsant activity of Compound 10 is

characterized by its effectiveness by the sc Met test and
to >100 for phenytoin. The PI. for phenobarbital is
ineffectiveness by the so Bic, sc Pic, and so Strych tests.
6.68. The P.I.’s for compounds active by the sc Met test
Thus, its pro?le of anticonvulsant action does not re
semble that of any of the four prototype agents. Pheno 20 range from 0.14 and 1.56 for Compound 10 and valpro
ate, respectively, to 18.76 for ethosuximide; the PI for
barbital and valproate, on the other hand, were effec
phenobarbital by this test is 5.29. Phenytoin is ineffec
tive by all four anticonvulsant tests. However, it should
tive by this test.
be noted that valproate was effective against strychnine
Phase VII studies of Compound 10 included ?ve-day
in nontoxic doses, whereas phenobarbital had to be

given in toxic doses in order to protect against this 25 LD3, ?ve-day tolerance studies, and effect of chronic
chemical convulsant. Phenytoin, on the other hand, was

administration on the liver microsomal enzyme system.

ineffective against Metrazol, bicuculline, and picrotoxin

The ?ve-day oral LD3 of Compound 10 is <300 mg/kg

and was only capable of providing protection in 50% of
animals given strychnine. Ethosuximide was effective

day tolerance studies in rats indicate that signi?cant

in male rats and >300 mg/kg in female rats. The ?ve

by the Sc Met, sc Bic, and sc Pic tests, and only pro 30 tolerance occurs within this period of time (MES test: 1
of 8 protected in chronic-treated group; 6 of 8 protected
tected a maximum of 62% of animals by the Sc Strych
in acute [single dose] control group; hexobarbital sleep
test. However, ethosuximide had to be given in toxic
time, 15.0i2.0 and 16.3: 1.2 min in chronic-treated and
doses to protect against sc Bic seizures.
acute control group, respectively. This interpretation is
In Phase VI studies, Anticonvulsant Quanti?cation in
Rats p.o., it was found that the TPE for Compound 10 35 further supported by the fact that there were signi?cant
increases in cytochrome P-450 (09881-0096 vs
in this species after oral administration was two hours
0720:0054 n moles/mg, p-nitroanisole O-demethylase
by the toxicity test and four hours by the MES and so
Met tests. The TPE of the other four compounds
(06401-0098 11 moles/mg/min in treated vs
0.261 i0.035 in controls), and cytochrome C reductase
ranged from one-half hour for valproate to ?ve hours

for phenobarbital.

40 (2195124 11 moles/mg/min in treated vs 157111 in con

With respect to anticonvulsant activity it may be seen
that after oral administration in rats, phenobarbital was
the most potent by the MES test (ED50: 9.14 mg/kg),

trols) of chronically treated rats as compared to the

acute (single dose) control group.

TABLE 5
QUANTITATIVE TOXICITY PROFILE OF
INTRAPERITONEALLY ADMINISTERED COMPOUND 10
AND SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE,
ADD No.

Time Rotorod
of Test TD5O

Substance

(hrs)

(mg/kg)

Compound 10

1, 1, 1 244.51

EDSO (mg/kg) and PI

MES

sc Met

Bicuculline

Picrotoxin

[116L125 NO

Strychnine

65.76

26.95

NO

(221.82-

(51.82-83.19)

(9.89-5508)

protection

protection

[E2] 1 pro
tected at 250; no

275.17)

[5.43]

[1.21]

up to 300

up to 300

protection at 300

[13.86]
Phenytoin

Phenobarbital

Ethosuximide

2, 2

3, 1, 1

65.46

9.50

No

No

(52.49-72.11)

(8.13-10.44)

@ No
Protection

Protection

Protection

EJE Maximum@
50% protection

[15.23]

[13.66]

up to 300

up to 100

up to 100

at 55-100

69.01

21.78

13.17

37.72

27.51

95.30

(62.84-72.89)

(14.99-25.52)

(5.87-1593)

(26.49-47.39)

(20.88-34.82)

(91.31-99.52)

[24.67]

[14.98]

[5.93]

[4.07]

[4.79]

[18.51]

No
protection

130.35
(11099-15045)

459.01
(34992-63513)

242.69 [E] MaximumE:
(22784-25522)
62% protection

up to 1000

[10.06]

[3.21]

[26.43]

1, 3, 1 440.83
(383.09485.34)

[12.37]

at 250-1000
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TABLE S-continued
QUANTITATIVE TOXICITY PROFILE OF
INTRAPERITONEALLY ADMINISTERED COMPOUND 10
AND SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE.
Time

ADD No.

Rotorod

-

of Test TDSO

Substance

(hrs)

Valproate

I, A, 4 425.84

EDSO (mg/kg) and P1

(mg/kg)

MES

60 Met

Bicuculline

Picrotoxin

Strychnine

271.66

148.59

359.95

387.21

(368.91-

(246.97-337.89)

(12264-17702)

(29407-43854)

(341.37-44438)

IE 292.96

(261.I2-3Z3.43)

450.40)
[20.84]

[12.83]

[11.87]

[7.51]

[8.35]

[11.80]

( ) 95% Con?dence interval

[ ] Slope, regression line
' Protective Index (P.1.) = TD50/ED5O

TABLE 6
PROFILE OF ANTICONVULSANT ACTIVITY
OF ORALLY ADMINISTERED COMPOUND 10 AND SOME
PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE AND RATS
TDSO
MES-EDSO

Time of Test

Add No.
Substance

(hrs)
Mice

(mg/kg)
Rats

Mice

sc Met-EDSO

(mg/kg)
Rats

Mice

(mg/kg)
Rats

Mice

Rats

44.48

Compound 10 6, 1, 1

2, 4, 4 729.08

(32.784261)

131.67

(49247-100917) [421]
[3.03]
Phenytoin

2, 2, 2 -, 4, 4 86.71
(80.39-96.09)

No ataxia up
to 3000

[13.01]

Phenobarbital

Ethosuximide

2, 2, 2

1, 8, 3

3, 5, 5 96.78

2, 1, 1

29.82 I < 100 I No
I<O.29 I No
(21.92-38.91)
Protection
Protection

[6.28]

[2.82]

up to 300

[E] 9.14

20.09

12.59

11.55

(14.73-31.58)

(7.58-1 1.86)

(7.99—] 1.86)

(7.75—15.00)

[8.51]

[3.00]

[5.20]

[4.12]

[4.12]

[4.08]

1012.31
No
@I No
|<0.84| 192.21 I 3.26 | 53.97 I18.76 I
(901.66-1109.3l) protection
protection
(l58.S9-438.61) (45.57-60.85)
[15.33]

up to 2000

up to 1200

[8.12]

[9.05]

1264.39

280.26

664.80

489.54

388.31

179.62

(800-2250)
[4.80]

(191.32-35276) (19132-35276) (351.14—728.37) (348.87-438.61) (14673-21035)
[4.63]
[4.63]
[2.90]
[8.12]
[8.62]

' Protective Index (P.I.) = TD50/ED50

TABLE 7
QUANTITATIVE TOXICITY PROFILE OF

Compound 10

Phenytoin

Phenobarbital

Ethosuximide

INTRAPERITONEALLY ADMINISTERED COMPOUND 10
AND SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE.
Time
of Test
DOSE 50 (mg/kg)

(hrs)

24, 6,1

Lethality

24.3.3

Righting Re?ex

[E

Rotorod

569.24
(52098-65059)

525.98
(47377-56448)

[14.55]

[20.18]

[13.86]

24, 12,2 229.61

241,]

up to 800

61.09

[ ] Slope. regression line

Substance

(83.41—5690.66)
[0.89]

9.04
(739-1062)

( ) 95% Con?dence intervaI

ADD N0.

(71.74-210.07)
[2.16]

(43.72-95.85)

2, 2, 2 879.21
(83949-93351)
lY g, 3

I 0.89’ I 13567 I 5.37* I 329.18 I 0.14‘ I

(7988-11500)

[305°]
Valproate

49.89

(10890-16574) (31.15-73.15)
[6.04]
[2.93]

244.51
(22282-27517)

178.34

65.46

(21644-25910)

(15293-19545)

(52.46-72.11

[15.89]

[14.03]

[15.23]

264.70

135.45

69.01

(24155-28552)
[15.95]

(11490-17742)
[8.41]

(62.84-72.89)
[24.67]

1752.23

850.61

(1607.02—1866.64) (75119-91793)
[14.75]
[16.43]

44.83

(38309-48534)
[18.37]

IE]

IE

[135
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TABLE 7-continued
QUANTITATIVE TOXICITY PROFILE OF
INTRAPERITONEALLY ADMINISTERED COMPOUND 10
AND SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE.
Time

ADD No.

of Test

Substance

(hrs)

Valproate

24, I, 1

DOSE 50 (mg/kg)
Righting Re?ex

Lethality

Rotorod

1104.62

885.53

(1021.54—l253.66)

(82086-94704)

425.84

(36831-45040)

[11.41]

[12.46]

[20.84]

( ) 95% Con?dence interval

[ ] Slope. regression line
' Protective Index {P.I.) = TDSO/EDSO

The pro?les of anticonvulsant activity of Compound 10
and the four prototype agents after intraperitoneal ad
ministration in mice and oral administration in mice and

respectively. Thus the ratios between either the minimal
toxic dose and the 24-hour lethal dose or the loss of
20

righting re?ex does and the 24-hour lethal dose for
Compound 10 are lower than those for any of the four

rats are summarized in Tables 5 and 6, respectively. It is
seen from Table 5 that, in terms of the pro?le of anti
candidate substances; hence, the margin between the
minimal toxic dose and the 24-hour lethal dose in mice
convulsant activity, Compound 10 does not resemble
is unusually narrow.
any of the four prototype agents. Unlike phenobarbital
The selectivity exhibited by Compound 10 and the
and valproate, Compound 10 is ineffective in doses up 25
four prototype agents as indicated by the slopes of the
to 300 mg/kg after i.p. administration in mice by the sc
regression lines derived from the MES, sc Met, rotorod
Bic, sc Pic, and so Strych tests, whereas phenobarbital
and valproate are effective by these tests. In terms of
loss of righting re?ex, and 24-hour lethality tests (mice,

rotorod toxicity, the Compound 10 is approximately

i.p.) is summarized below:

Correlation Between the Slopes of the Regression Lines
for Compound 10 and the Prototype Agents

Right.

Deaths

MES

Sc Met

Rotorod

Re?ex

24 hours

Compound

Compound

Compound

Compound

Compound

Prototype

l0

l0

10

10

1O

Phenytoin

‘

"

X

‘

X

Phenobarbital

‘

'

"

‘

Ethosuximide

‘

‘

*

Valproate

‘

‘

*

X

X

“

X

X Correlates with indicated prototype to a certain extent

‘Does not correlate well with prototype agent.

It may be seen from the above summary that in terms of

twice as toxic as either ethosuximide or valproate in this
species. It may be seen from Table 6 that after oral

selectivity of effect as indicated by the slope of the

administration, Compound 10 is approximately 16 times

regression lines, Compound 10 resembles phenytoin by

more neurotoxic in rats than it is in mice; likewise, Com 50 the rotorod test; ethosuximide by the righting re?ex
test; and all the prototype agents by the 24-hour lethal
pound 10 is about 2% times more potent by the sc Met
ity test. In marked contrast, Compound 10 does not
test in mice than in rats. It should be noted that phenyt

oin administered orally in higher doses is absorbed only

resemble any of the prototype agents by either the MES

to a limited extent from the gastrointestinal tract of rats.

or sc Met tests. The reason Compound 10 does not

Consequently, no minimal neurotoxicity was observed 55 resemble the prototype agents by the MES test is due to

in this species even in doses up to 3000 mg/kg (see

flatter slopes of the regression lines (5.43 for Compound

Table 6).
The quantitative toxicity pro?les after intraperitone
ally administering Compound 10 and the four prototype

tal, and valproate, respectively); similarly, Compound

seen that the times of peak toxicity for phenytoin by the

tal, ethosuximide and valproate, respectively).

10 vs 13.66, 14.98, and 12.83 for phenytoin, phenobarbi

10 has a much ?atter slope by the sc Met test (1.21 for
agents in mice are summarized in Table 7. It may be 60 Compound 10 vs 5.93, 10.06, and 11.84 for phenobarbi

rotorod and righting re?ex tests are 2 and 12 hours,

respectively, whereas the TPE for Compound 10 by the

Since all protective indices (P.I.‘s) are based on the

assumption that the slope of the regression lines (toxic

ity and activity) are parallel, it is important to note the
righting re?ex test is 6 hours. The TPE for the other
three prototype agents by the rotorod and righting 65 effect of slope on the’ safety ration (SR=TD3/ED97)
re?ex tests range from one-fourth to one hour. This

for Compound 10, phenobarbital, and valproate. The

table also shows that the LDSO/HDSO and
LD50/TD50 ratios for Compound 10 are 1.08 and 2.33,

safety ratios of these substances are summarized below.

4,610,994
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Safety Ratios‘ (TD3/ED97) of Compound 10,
Phenobarbital, and Valproate
Substance and Test

Species &
Parameter

Compound 10

Phenobarbital

Valproate

Route Admin.

MES

sc Met

MES

sc Met

MES

TD3

Mice, i.p.

175

175

57

57

345

345

ED97
Ratio

"

145
1.2

900
0.2

29
2.3

27
2.5

380
0.9

218
1.6

TD3

Mice, oral

173

173

58

58

500

500

ED97
Ratio
TD3
ED97

"

275
0.6
l6
215

980
0.2
l6
> 10000

46
1.3
l4
26

38
1.5
14
34

840
0.6
115
1800

680
0.7
115
188

0.5

0.4

0.1

0.6

Ratio

Rats, oral
"

0.07

0.002

sc Met

‘Ratios less than 1 indicate that 97% protection is obtained only with some minimal neurotoxicity.

The above summary indicates that after intraperito
neal administration of nontoxic doses, the test substance
Compound 10 are the favorable safety ratios,
(Compound 10) will protect 97% of mice subjected to
the MES test, whereas toxic doses are required to pro 20 TD3/ED97 by the MES test and 24-hour LD50/ED50
by the sc Met test. The disadvantages are related to a

vide this same level of protection by the sc Met test.
After oral administration of the test substance in mice
and rats, toxic doses are required to protect 97% of
animals by either the MES or so Met test. Moreover,

lack of selectivity (?at regression line) by the MES test,
the unfavorable ratio (TD3/ED97) by the sc Met test,
and the toxicity ratios (24-hour LDSO/HDSO and 24

hour LDSO/TD50).

the candidate substance (Compound 10) and the two
prototype agents used for comparison of the safety
ratios do not provide 97% protection by the MES and

The invention has been described herein with refer
ence to certain preferred embodiments. However, as
obvious variations thereon will become apparent to
those skilled in the art, the invention is not to be consid
ered as limited thereto.
I claim:

sc Met tests in nontoxic doses after oral administration
in rats.

For a candidate drug to be useful in man, it should be
adequately absorbed after oral administration. The ex
tent of oral absorption can be determined from the ratio
of the oral ED50/i.p. ED50 for a desired pharmaco
logic activity and should be equal to or less than 4 for

1. A compound of the following formula:

R2
adequate absorption. The oral TD50/i.p. TD50 and oral 35
ED50/i.p. ED50 ratios for Compound 10 in mice are
2.98, 2.00, and 5.03 by the rotorod MES, and se Met
tests, respectively. This suggests that Compound 10 is
adequately absorbed in mice after oral administration.
Chronic studies indicate that Compound 10 is more 40 wherein R1 is 4-pyridyl, or 3-pyridyl and R1 is m

toxic in male than in female rats. Thus, the estimated

methyl, m- or p-?uoro, m-chloro, m- or p-bromo, m- or

?ve-day LD3 for Compound 10 is <300 mg/kg in male
rats and >300 but <1000 mg/kg in female rats. The

?ve-day chronic studies also demonstrate that signi?
cant toleance to the anticonvulsant effects of Com 45

pound 10 develops in rats within this short period of

time. This interpretation is con?rmed, not only by the
marked difference in response to the MES test (single
dose of 50 mg/kg, 6 of 8 rats protected; ?ve daily doses
of 50 mg/kg, 1 of 8 protected), but also by the signi?

4-pyridyl and R2 is 3,5-dichloro.
5. A compound according to claim 1 wherein R1 is
50

cant increase observed in liver cytochrome P-450

3-pyridyl and R2 is para-bromo.

chrome C reductase (40%).

7. A compound according to claim 1 wherein R1 is

For a candidate antiepileptic substance to be useful in

3-pyridyl and R2 is para-?uoro.

the treatment of seizure disorders, its experimental pro
?le of action should compare favorably with that of

8. A compound according to claim 1 wherein R1 is

3-pyridyl and R2 is 3,4-dichloro.
9. A compound according to claim 1 wherein R1 is

4-pyridyl and R2 is meta-fluoroi
10. A compound according to claim 1 wherein R1 is
60

toxicity (LDSO, HDSO, and TD50), protective indices
(TD50/ED50), safety ratios (TD3/ED97), absorption

ate shows the relative merits and the disadvantages of
Compound 10. The merits of the candidate substance

4-pyridyl and R2 is meta-bromo.
11. A compound according to claim 1 wherein R1 is

4-pyridyl and R2 is meta-methyl.

characteristics (oral ED50/i.p. ED50 and oral

TD50/i.p. TD50) and the margin of safety (single dose
?ve-day LDSO/EDSO). An analysis of the data for
Compound 10, phenobarbital, ethosuximide and valpro

3-pyridyl and R2 is para-chloro.
6. A compound according to claim 1 wherein R1 is

(37%), p-nitroanisole O-demethylase (145%), and cyto

clinically useful antiepileptic drugs. Such a comparison
should include not only the anticonvulsant efficacy
(ED50), but also the selectivity of toxic and anticonvul
sant effects (slope of the dose-effect regression line),

p-tri?uoromethyl, 3,4-dichloro, or 3,5-dichloro.
2. A compound according to claim 1 wherein R1 is
4-pyridyl and R2 is meta-chloro.
3. A compound according to claim 1 wherein R1 is
4~pyridyl and R2 is 3,4-dichloro.
4. A compound according to claim 1 wherein R1 is

12. A compound according to claim 1 wherein R1 is

4-pyridyl and R2 is meta-trifluoromethyl.
65

13. A compound according to claim 1 wherein R1 is

3-pyridyl and R2 is para-tri?uoromethyl.
14. A compound according to claim 1 wherein R1 is

4-pyridyl and R2 is para-fluoro.

23
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27. A composition according to claim 1 wherein R1 is

15. An anticonvulsant composition comprising an
effective amount of a compound selected from the
group consisting of those of the formulae:

Z-pyridyl and R2 is para-chloro.
28. A composition according to claim 1 wherein R1 is
4-pyridyl and R1 is meta-fluoro.
29. A composition according to claim 1 wherein R1 is
4-pyridyl and R2 is meta-bromo.
30. A composition according to claim 1 wherein R1 is

4-pyridyl and R2 is meta-methyl.
31. A composition according to claim 1 wherein R1 is

4-pyridyl and R2 is meta-tri?uoromethyl.
32. A composition according to claim 1 wherein R1 is

wherein R1 is 4-pyridyl, 3-pyridyl, or 2-pyridyl and R2

3-pyridyl and R2 is para-trifluoromethyl.

is hydrogen, m- or p-methyl, p-methoxy, m- or p~

33. A composition according to claim 1 wherein a
sufficient amount of the effective ingredient is con
fluoromethyl, 3,4-dichloro or 3,5-dichloro and a phar 15 tained in said composition to provide a dosage amount
chloro, m- or p-bromo, m- or p-fluoro, m- or p-tri

maceutically acceptable carrier or adjuvent.
16. A composition according to claim 1 wherein R1 is
4-pyridyl and R2 is hydrogen.
17. A composition according to claim 1 wherein R1 is
4-pyridyl and R2 is para-?uoro.
18. A composition according to claim 1 wherein R1 is
4-pyridyl and R2 is para-methyl.
19. A composition according to claim 1 wherein R1 is
4-pyridyl and R2 is para-methoxy.
20. A composition according to claim 1 wherein R1 is
4-pyridyl and R2 is meta-chloro.
21. A composition according to claim 1 wherein R1 is
4-pyridyl and R2 is 3,4-dichloro.

ranging from about 25 mg/kg to 300 mg/kg.
34. A method for the treatment of convulsive disor
ders in mammals which comprises administration
thereto of an effective dosage amount of a composition
of claim 23.
35. A method for the treatment of convulsive disor

ders in mammals which comprises administration
thereto of an effective dosage amount of an anticonvul
sant composition comprising an effective amount of a
25

compound selected from the group consisting of those
of the formulae:

22. A composition according to claim 1 wherein R1 is 30
4-pyridyl and R2 is 3,5-dichloro.

I
23. A composition according to claim 1 wherein R1 is

3-pyridyl and R2 is para-chloro.
24. A composition according to claim 1 wherein R1 is

3-pyridyl and R2 is para-bromo.

wherein R1 is 4-pyridyl, 3-py‘ridyl, Z-pyridyl or phenyl

35 and R2 is hydrogen, m- or p-methyl, p-methoxy, m- or

25. A composition according to claim 1 wherein R1 is

p-chloro, m- or p-bromo, m- or p-fluoro, m- or p-tri

3-pyridyl and R2 is para-?uoro.

?uoromethyl, 3,4-dichloro or 3,5-dichloro and a phar
maceutically acceptable carrier or adjuvent.

26. A composition according to claim 1 wherein R1 is

ll‘

3-pyridyl and R2 is 3,4-dichloro.
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